Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Lederman ER[original query] |
---|
Serological susceptibility to varicella among U.S. Immigration and Customs Enforcement detainees
Varan AK , Lederman ER , Stous SS , Elson D , Freiman JL , Marin M , Lopez AS , Stauffer WM , Joseph RH , Waterman SH . J Correct Health Care 2017 24 (1) 1078345817727287 U.S. Immigration and Customs Enforcement (ICE) is responsible for detaining unauthorized aliens during immigration proceedings. During 2014 to 2015, adult ICE detainees at a California facility were invited to complete a survey concerning self-reported varicella history and risk factors. Participants underwent serological testing for varicella-zoster virus (VZV) IgG; susceptible individuals were offered varicella vaccination. Among 400 detainees with available serology results, 48 (12%) were susceptible to varicella. Self-reported varicella history was negatively associated with susceptibility (adjusted odds ratio = 0.16; 95% confidence interval [0.07, 0.35]). Among 196 detainees reporting a positive history, 95% had VZV IgG levels suggestive of varicella immunity. Among 44 susceptible detainees offered vaccination, 86% accepted. Given relatively high varicella susceptibility, targeted screening and vaccination among ICE detainees lacking a positive history might reduce varicella transmission risks. |
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246 and CMX001
Lederman ER , Davidson W , Groff HL , Smith SK , Warkentien T , Li Y , Wilkins KA , Karem KL , Akondy RS , Ahmed R , Frace M , Shieh WJ , Zaki S , Hruby DE , Painter WP , Bergman KL , Cohen JI , Damon IK . J Infect Dis 2012 206 (9) 1372-85 Progressive vaccinia (PV) is a rare but potentially lethal complication which develops in smallpox vaccine recipients with severely impaired cellular immunity. We report a patient with PV requiring treatment with vaccinia immune globulin and who received two investigational agents, ST-246 and CMX001. We describe the various molecular, pharmacokinetic, and immunologic studies which provided guidance to escalate and then successfully discontinue therapy. Despite development of resistance to ST-246 during treatment, the patient had resolution of his PV. This case demonstrates the need for continued development of novel anti-orthopoxvirus pharmaceuticals and the importance of both intensive and timely clinical and laboratory support in management of PV. |
Risk factors for severe Rift Valley fever infection in Kenya, 2007
Anyangu AS , Gould LH , Sharif SK , Nguku PM , Omolo JO , Mutonga D , Rao CY , Lederman ER , Schnabel D , Paweska JT , Katz M , Hightower A , Njenga MK , Feikin DR , Breiman RF . Am J Trop Med Hyg 2010 83 14-21 A large Rift Valley fever (RVF) outbreak occurred in Kenya from December 2006 to March 2007. We conducted a study to define risk factors associated with infection and severe disease. A total of 861 individuals from 424 households were enrolled. Two hundred and two participants (23%) had serologic evidence of acute RVF infection. Of these, 52 (26%) had severe RVF disease characterized by hemorrhagic manifestations or death. Independent risk factors for acute RVF infection were consuming or handling products from sick animals (odds ratio [OR] = 2.53, 95% confidence interval [CI] = 1.78-3.61, population attributable risk percentage [PAR%] = 19%) and being a herds person (OR 1.77, 95% CI = 1.20-2.63, PAR% = 11%). Touching an aborted animal fetus was associated with severe RVF disease (OR = 3.83, 95% CI = 1.68-9.07, PAR% = 14%). Consuming or handling products from sick animals was associated with death (OR = 3.67, 95% CI = 1.07-12.64, PAR% = 47%). Exposures related to animal contact were associated with acute RVF infection, whereas exposures to mosquitoes were not independent risk factors. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure